Gut hormones as peripheral anti obesity targets

Area of Science:

• Endocrinology
• Gastroenterology
• Pharmacology

Background:

• Gastrointestinal (GI) peptides regulate GI function and influence eating behavior, presenting potential anti-obesity targets.
• Obesity is a major global health concern with accelerating prevalence and significant mortality.
• Naturally occurring gut hormones and their receptor interactions are key to understanding and potentially treating obesity.

Purpose of the Study:

• To explore the therapeutic potential of gut hormones and their G-protein coupled receptors (GPCRs) for obesity treatment.
• To review the mechanisms by which specific gut hormones influence food intake and appetite.
• To assess the efficacy of exogenous gut hormone administration in modulating eating behavior.

Main Methods:

• Review of existing literature on gut hormone function and their roles in appetite regulation.
• Analysis of studies involving peripheral and central administration of gut hormones in animal models and humans.
• Examination of the specific GPCRs (e.g., NPY Y2, GLP-1 receptor, GHS-R) mediating hormone actions.

Main Results:

• Peripheral administration of Peptide YY (PYY 3-36) significantly inhibits food intake in mice, rats, and humans, including obese individuals.
• Glucagon-like peptide 1 (GLP-1) and oxyntomodulin decrease food intake via peripheral or central administration, acting through the GLP-1 receptor.
• Ghrelin administration increases food intake and appetite, with chronic administration leading to obesity, acting via the growth hormone secretagogue receptor (GHS-R).

Conclusions:

• Gut hormones like PYY, GLP-1, and oxyntomodulin represent promising therapeutic targets for obesity management.
• Understanding the signaling pathways of gut hormones through their respective GPCRs is crucial for developing effective anti-obesity strategies.
• Exogenous administration of certain gut hormones offers a potential long-term therapeutic approach for weight control.